SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities

Exchange Act of 1934

Date of Report (Date of earliest event reported): May 17, 2011

Vermillion, Inc.

(Exact name of registrant as specified in its charter)

Commission File Number: 001-34810

12117 Bee Caves Road Building Two, Suite 100, Austin, TX 78738

(Address of principal executive offices, including zip code)

512.519.0400

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

On May 17, 2011, the board of directors (the “Board”) of Vermillion, Inc. (the “Company”) approved the appointment of Bruce A. Huebner to its Board as a Class I director, with a current term that will expire at the annual meeting of stockholders to be held in 2013. Mr. Huebner is expected to lead a special committee of the Board to evaluate the current sales and marketing strategy for the Company’s OVA1^® Ovarian tumor triage test. Mr. Huebner is also expected to receive compensation consistent with the Company’s compensation policy for his service as a non-employee director, as specified from time to time by the Board.

Mr. Huebner, age 60, currently serves as a managing director for LynxCom Partners, LLC, a healthcare consulting firm with expertise in pharmacy, nursing, biotechnology, clinical diagnostics, durable medical equipment, payer relations, regulatory compliance, business development and operations. From October 2009 to June 2010, Mr. Huebner served as President and Chief Executive Officer of TrovaGene, Inc., a developer of molecular diagnostics products based on the detection of transrenal genetic markers. From May 2005 to July 2008, Mr. Huebner served as President of Osmetech Molecular Diagnostics, where he successfully established Osmetech as a fully integrated business, obtaining FDA clearance for four molecular diagnostic microarray products and introducing them to the marketplace. From 2002 to 2004, Mr. Huebner was President and Chief Operating Officer of Nanogen, Inc., a publicly held nanotechnology/microarray company. From 1996 to 2002, Mr. Huebner was Executive Vice President and Chief Operating Officer of Gen-Probe, Inc. which today is one of the world leaders in the development of nucleic acid tests, including a focus on diagnostic tests for infectious disease that affect women’s health. Mr. Huebner’s other experience includes Vice President of Marketing and Sales at Quidel, Director of Marketing for the U.S. and Director of Marketing and Market Development in Europe for Hybritech, Inc., and various sales and marketing positions at Roche Diagnostics. He currently serves as a director on the board of directors of Pasadena Bioscience Collaborative and Corgenix Medical Corporation. Mr. Huebner received his Bachelor of Science degree in Chemistry and Biology from University of Wisconsin—La Crosse and completed a graduate school senior executive program at Columbia University.

On May 19, 2011, the Company issued a press release announcing the appointment of Bruce Huebner to the Board of Directors. A copy of the Company’s press release dated May 19, 2011 is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EXHIBIT INDEX